Summary
Plasma and tissue levels of doxorubicin (DXR) and doxorubicinol (DXR-OL) were measured fluorometrically after high-pressure liquid chromatography at 1, 3, and 24 h following one, nine, and 24 doses of 1.0 mg DXR/kg or one and eight doses of 4.0 mg DXR/kg, IP, to rats. Comparison of plasma levels of DXR found following single and multiple doses suggests significant build-up of DXR at 1 h with successive doses, but not at 3 h. Liver exhibited substantially higher levels of DXR (on a per gram of protein basis) than did plasma, and multiple doses did not produce higher levels than did a single dose. In contrast, the heart accumulated DXR slowly, attaining levels after multiple dosing in excess of those found in the liver. Skeletal muscle exhibited dose-related levels similar to those for heart but the absolute levels of DXR in muscle were only about one-tenth of those observed in heart. DXR-OL was at very low levels of ≤4% of the DXR levels in the tissues; it was, however, a major circulatory metabolite, attaining levels in the plasma as high as 85% of the concentration of DXR.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bearden JC Jr (1978) Quantitation of submicrogram quantities of protein by an improved protein-dye binding assay. Biochim Biophys Acta 533:525
Benjamin R, Legha S, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen S, Blumenschein G, Freireich E (1981) Reduction of adriamycin cardiac toxicity using a prolonged continuous intravenous infusion. Proc Am Assoc Cancer Res 22:179
Blanchard JC, Schneider Y-J, Baurain R, Trouet A (1981) Accumulation, metabolism, and subcellular localization of daunorubicin, doxorubicin and their DNA-complexes in rat heart ventricles. Eur J Cancer 17:297
Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80:249
Carter SK (1975) Adriamycin — a review. J Natl Cancer Inst 55:1265
Chan KK, Cohen JL, Gross JF, Himmelstein KJ, Bateman JR, Yeu T-L, Marlis AS (1978) Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep 62:1161
Chlebowski RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, Bateman JR (1980) Adriamycin given on a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47
Fenimore DC, Davis CM, Whitford JH, Harrington CA (1976) Vapor phase silylation of laboratory glassware. Anal Chem 48:2289
Jensen RA (1981) Electrocardiographic effects of N,N-dibenzyldaunorubicin (B2D) and doxorubicin (DXR) in the rat. Proc Am Assoc Cancer Res 22:269
Olson HM, Capen CC (1978) Chronic cardiotoxicity of doxorubicin (adriamycin) in the rat: morphologic and biochemical investigations. Toxicol Appl Pharmacol 44:605
Ozols RF, Willson JKV, Weltz MD, Grotzinger KR, Myers CE, Young RC (1980) Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res 40:4109
Peters JH, Murray JR Jr (1979) Determination of adriamycin and aclacinomycin A in plasma by high pressure liquid chromatography and spectrophotofluorometry. Journal of Liquid Chromatography 2:45
Shinozawa S, Mimaki Y, Araki Y (1980) Determination of the concentration of adriamycin and its metabolites in the serum and tissues of Ehrlich carcinoma-bearing mice by high-performance liquid chromatography. J Chromatogr 196:463
Siemann DW, Sutherland RM (1979) A comparison of the pharmacokinetics of multiple and single dose administrations of adriamycin. Int J Radiat Oncol Biol Phys 5:1271
Smith TH, Fugiwara AN, Henry DW (1979) Synthesis of daunorubicin analogues with novel 9-acyl substituents. J Med Chem 22:40
Tavoloni N, Guarino AM (1980) Disposition and metabolism of adriamycin in the rat. Pharmacology 21:244
Weiss AJ, Manthel RW (1977) Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity. Cancer 40:2046
Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TS, Ramirez G (1976) Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813
Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, Maggia FM (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710
Zbinden G, Backmann E, Holderegger C (1978) Model systems for cardiotoxic effects of anthracyclines. Antibiot Chemother 23:255
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Peters, J.H., Gordon, G.R., Kashiwase, D. et al. Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin. Cancer Chemother. Pharmacol. 7, 65–69 (1981). https://doi.org/10.1007/BF00258216
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00258216